NATCOPHARMA presents compelling buy-side technical opportunity consolidating above pivot ₹972.07 support (S1 ₹969.44/S2 ₹967.87) from deeply oversold STOCH(13.74), STOCHRSI(5.76), Williams %R(-93.67) signaling capitulation exhaustion after recent correction near 200-MA ₹965.74 Buy support, despite short-term bearish MA cluster (10/12 Sell).
Narrowing MACD(-14.57) alongside neutral RSI(31.32) confirms downside momentum depletion creating favorable risk-reward near S3 ₹965.24 zone, with higher lows formation validating accumulation base.
Attractive long entry targeting R1 ₹973.64/R2 ₹976.27/R3 ₹977.84 breakout with tight stops below S2 ₹967.87 for optimal rebound capture in this pharma leader amid US generics tailwinds.
Warning-
Disclaimer– Registration granted by SEBI, membership of a SEBI recognized supervisory body (BSE) and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.
Disclosure– Investments in securities market are subject to market risks, read all the related documents carefully before investing.